We are asking our members to help us understand how TTS can better serve you!
Take the TTS 2021 Needs Assessment Survey.
Results of the survey will directly impact TTS activities!
Participate by: February 12, 2021Click here to take the survey
During December 14 to 23,2020, after administration of a reported 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine, CDC identified 21 case reports submitted to VAERS that met Brighton Collaboration case definition criteria for anaphylaxis, corresponding to an estimated rate of 11.1 cases per million doses administered. Four patients (19%) were hospitalized (including 3 in intensive care), and 17 ( 81%) were treated in an emergency department; 20 (95%) are known to have been discharged home or had recovered at the time of the report to VAERS. No deaths from anaphylaxis were reported. Median interval from vaccine receipt to symptom onset was 13 minutes (range, 2-150 minutes). Seventeen (81%) of 21 patients with anaphylaxis had a documented history of allergies or allergic reactions.
The authors conducted a prospective cohort study through the Improving Renal Outcomes Collaborative (IROC) to collect clinical outcomes data about COVID-19 in pediatric kidney transplant patients. Twenty-two IROC centers that care for 2732 patients submitted testing and outcomes data for 281 patients tested for SARS-CoV-2 by PCR. Testing indications included symptoms and/or potential exposures to COVID-19 (N=134, 47.7%) and/or testing per hospital policy (N=154, 54.8%). Overall, 24 (8.5%) patients tested positive, of which 15 (63%) were symptomatic. Of the COVID-19 positive patients, 16 were managed as outpatients, 6 received non-ICU inpatient care and 2 were admitted to the ICU. There were no episodes of respiratory failure, allograft loss, or death associated with COVID-19. To estimate incidence, sub-analysis was performed for thirteen centers that care for 1686 patients that submitted all negative and positive COVID-19 results. Of the 229 tested patients at these 13 centers, 10 (5 asymptomatic) patients tested positive, yielding an overall incidence of 0.6% and an incidence among tested patients of 4.4%. Pediatric kidney transplant patients in the U.S. had a low estimated incidence of COVID-19 disease and excellent short-term outcomes.
This is a randomized phase 2/3 trial at 49 US centers including ambulatory patients (N = 613) who tested positive for SARS-CoV-2 infection and had 1 or more mild to moderate symptoms. Patients who received bamlanivimab monotherapy or placebo were enrolled first (June 17-August 21, 2020) followed by patients who received bamlanivimab and etesevimab or placebo (August 22-September 3). Patients were randomized to receive a single infusion of bamlanivimab (700 mg [n = 101], 2800 mg [n = 107], or 7000 mg [n = 101]), the combination treatment (2800 mg of bamlanivimab and 2800 mg of etesevimab [n = 112]), or placebo (n = 156). Among nonhospitalized patients with mild to moderate COVID-19 illness, treatment with bamlanivimab and etesevimab, compared with placebo, was associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11; no significant difference in viral load reduction was observed for bamlanivimab monotherapy.
Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications. These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment.
The Editors of Transplantation and Transplantation Direct are seeking expressions of interest for the role of Editorial Fellow.
The Fellowship is designed for an early career professional in transplantation interested in being on the frontlines of Transplantation, the most cited journal in transplantation, and Transplantation Direct, our open access journal.
The participant will identify the impact of clinical research on patient outcomes in the area of transition from hospital to home and chronic illness care for parents of pediatric solid organ transplant recipients.
Women in Transplantation (WIT) initiative of The Transplantation Society will provide funding to an Early Career Researcher to support research focusing on sex and gender issues relevant to solid organ transplantation.
This initiative was made possible with support with One Lambda, a Thermo Fisher Scientific brand, and Sanofi, with each supporting one award.
The spectrum of studies includes basic, clinical and translational. This individual should have spent two years or less performing research relevant to solid organ transplantation since obtaining their last degree (PhD, MD, MSc, PharmD, or equivalent). This work may represent a continuation of current research or a novel aspect of work. The mentor should have expertise in transplantation or immunology but need not be an investigator with known expertise in gender or sex.
Thursday February 25th 2021
Dear Women in Transplantation and TTS members,
The Asian Society of Transplantation (AST - myasot.org) in collaboration with the TTS Women in Transplantation (WIT) initiative are hosting two webinars on Gender Disparity in Transplant in Asia.
Thursday, January 28, 2021 (19:00 Seoul / Tokyo time - GMT+9)
TID has expanded their "Guidance on Coronavirus Disease 2019 (COVID-19) for Transplant Clinicians” to include a new section (Section #7) entitled "Guidance Focused Review on SARS-CoV-2 Vaccines in Transplant Recipients
Jan. 18 - Socioeconomic deprivation was found to be associated with poorer outcomes after liver transplantation in pediatric patients, according to study data presented at The Liver Meeting Digital Experience, held online from November 13 to 16, 2020. However, high-performing transplantation centers were associated with better long-term outcomes, regardless of socioeconomic strata.
Jan. 18 - Researchers at the University of Washington have developed a technique to modify naturally occurring biological polymers with protein-based biochemical messages that affect cell behavior. Their approach, published the week of Jan. 18 in the Proceedings of the National Academy of Sciences, uses a near-infrared laser to trigger chemical adhesion of protein messages to a scaffold made from biological polymers such as collagen, a connective tissue found throughout our bodies.